- Date 16 Feb 2023
Cambridge Molecular Diagnostics Limited is proud to announce the launch of a new lateral flow test for the detection of Mycoplasma contamination. This innovative easy-to-use,
rapid test uses an adapted PCR method and provides accurate results within minutes, making it a valuable tool for laboratories and manufacturers in academia and the biotech and pharmaceutical industries. The test has been fully validated, including evaluation within the University of Cambridge.
Mycoplasma are small, parasitic bacteria and contamination is a common problem in cell culture, leading to inaccurate research results and costly delays in product development. Traditional methods for detecting Mycoplasma, such as qPCR and culture, can take several days to yield results. The new lateral flow test, the SwiftDx Mycoplasma Detection Kit, offers a faster and more convenient solution.
The SwiftDx Mycoplasma Detection Kit uses small sample taken directly from the
cell culture media supernatant, with no interruption of cell growth, and provides
results in a simple, easy-to-read format. The test is highly sensitive and specific, with
a detection limit of less than 10 cfu/mL after day 3 of culture. It is time and costeffective,
making it a valuable addition to any laboratory’s Mycoplasma detection
arsenal. This new test will be a valuable tool for researchers and biomanufacturers
to ensure the quality and integrity of their cell culture systems, and ultimately improve the reproducibility of their research.
The SwiftDx Mycoplasma Detection Kit is available now and can be ordered through SwiftDx’s website or by contacting SwiftDx directly.